<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05000684</url>
  </required_header>
  <id_info>
    <org_study_id>JS004-006-I/II-LC</org_study_id>
    <nct_id>NCT05000684</nct_id>
  </id_info>
  <brief_title>Study of JS004 Combined With Toripalimab for Advanced Lung Cancer</brief_title>
  <official_title>A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab in Patients With Advanced Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Junshi Bioscience Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label phase I/II study to evaluate the safety, tolerability, pharmacokinetics&#xD;
      and initial efficacy of JS004 injection combined with toripalimab in patients with advanced&#xD;
      lung cancer who have failed standard therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of adverse events (AE) and serious adverse events (SAE) were assessed</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence and severity of adverse events (AE) and serious adverse events (SAE) as assessed according to NCI-CTCAE 5.0, as well as abnormalities in vital signs, electrocardiogram, and laboratory tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>2 years</time_frame>
    <description>Duration of Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>2 years</time_frame>
    <description>Duration of Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>2 years</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>2 years</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>2 years</time_frame>
    <description>Maximum Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>2 years</time_frame>
    <description>Time to Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>2 years</time_frame>
    <description>Area under the concentration versus time curve from time 0 to the last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>2 years</time_frame>
    <description>AUC from time 0 to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kel</measure>
    <time_frame>2 years</time_frame>
    <description>Elimination rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>2 years</time_frame>
    <description>Elimination half life time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>2 years</time_frame>
    <description>Clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F</measure>
    <time_frame>2 years</time_frame>
    <description>Apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rac</measure>
    <time_frame>2 years</time_frame>
    <description>Accumulation factor</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Advanced Lung Cancer</condition>
  <arm_group>
    <arm_group_label>JS004 200 mg in combination with toripalimab 240 mg was administered every 3 weeks as planned</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JS004 in combination with toripalimab</intervention_name>
    <description>Usage and dosage: Inject 200mg once every 3 weeks</description>
    <arm_group_label>JS004 200 mg in combination with toripalimab 240 mg was administered every 3 weeks as planned</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria：&#xD;
&#xD;
          1. Sign the informed consent form voluntarily;&#xD;
&#xD;
          2. Patient (both sex) ≥ 18 years at the time of signing informed consent;&#xD;
&#xD;
          3. Expected survival ≥ 3 months;&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;&#xD;
&#xD;
          5. Extensive-stage small cell lung cancer (ES-SCLC, according to the Veterans&#xD;
             Administration Lung Study Group VALG Staging) or/and locally advanced (stage&#xD;
             IIIB/IIIC), metastatic or recurrent (stage IV) non-small cell lung cancer (NSCLC) by&#xD;
             pathologically confirmed&#xD;
&#xD;
          6. At least one measurable lesion as a target lesion (RECIST v1.1 criteria);&#xD;
&#xD;
          7. Agree to provide tumor tissue samples (provide fresh biopsy samples before treatment&#xD;
             as far as possible; provide archived samples within 2 years for patients who cannot&#xD;
             provide fresh biopsy samples before treatment;&#xD;
&#xD;
          8. The subject has good organ function as indicated by screening laboratory results&#xD;
&#xD;
          9. Males of reproductive potential or females of childbearing potential must use&#xD;
             effective contraceptive methods (such as oral contraceptives, intrauterine device or&#xD;
             barrier method combined with spermicide) during the trial and continue contraception&#xD;
             for 6 months after the end of treatment;&#xD;
&#xD;
         10. Good compliance and cooperated with the follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any malignancy other than the disease under study within the past 5 years, except for&#xD;
             malignancies that can be expected to be cured after treatment (including but not&#xD;
             limited to adequately treated thyroid cancer, carcinoma in situ of the cervix, basal&#xD;
             or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated&#xD;
             surgically with curative intent);&#xD;
&#xD;
          2. Patients previously treated with anti-BTLA or anti-HVEM antibodies;&#xD;
&#xD;
          3. Patients previously discontinued treatment due to PD-1/PD-L1 inhibitor toxicity;&#xD;
&#xD;
          4. Any adverse reactions caused by previous treatments have not recovered to CTCAE v5.0&#xD;
             Grade 1 or below (except alopecia and neurotoxicity, which cannot be recovered due to&#xD;
             long-term presence as judged by the investigator);&#xD;
&#xD;
          5. Received allogeneic hematopoietic stem cell transplantation or solid organ&#xD;
             transplantation in the past;&#xD;
&#xD;
          6. A large amount of hydrothorax or ascites or pericardial effusion with clinical&#xD;
             symptoms or requiring symptomatic treatment;&#xD;
&#xD;
          7. Pulmonary disease: interstitial pneumonia, obstructive pulmonary disease and&#xD;
             symptomatic bronchospasm;&#xD;
&#xD;
          8. Active infection requiring systemic therapy;&#xD;
&#xD;
          9. A positive result for human immunodeficiency virus (HIV) antibody test;&#xD;
&#xD;
         10. Known active tuberculosis (TB). For patients with suspicion of active TB should&#xD;
             perform the test of chest X-ray, sputum, clinical signs and symptoms to exclude.&#xD;
&#xD;
         11. Have a history of psychotropic drug abuse and unable to withdraw or have mental&#xD;
             disorders;&#xD;
&#xD;
         12. Pregnant or lactating woman;&#xD;
&#xD;
         13. Known to be allergic to JS004 or toripalimab and its components;&#xD;
&#xD;
         14. Other severe, acute or chronic medical or psychiatric disorders or laboratory&#xD;
             abnormalities that, in the investigator's opinion, may increase the risk associated&#xD;
             with study participation or may interfere with the interpretation of study results.&quot;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaoyao Tian, MD</last_name>
    <phone>13514257836</phone>
    <email>xiaoyao_tian@junshipharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Cheng, Doctor</last_name>
      <phone>+8643180596067</phone>
      <email>jl.cheng@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jie Wang, MD</last_name>
      <phone>13910704699</phone>
      <email>zlhuxi@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>September 5, 2021</last_update_submitted>
  <last_update_submitted_qc>September 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

